Caribou Biosciences (CRBU) Stock Forecast & Price Target

$1.98

+0.04 (+2.06%)

(As of 09/27/2024 08:50 PM ET)

Caribou Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 4 Analyst Ratings

Sell
0

Hold
1

Buy
3

Based on 4 Wall Street analysts who have issued ratings for Caribou Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for CRBU.

Consensus Price Target

$11.25
468.18% Upside

According to the 4 analysts' twelve-month price targets for Caribou Biosciences, the average price target is $11.25. The highest price target for CRBU is $19.00, while the lowest price target for CRBU is $3.00. The average price target represents a forecasted upside of 468.18% from the current price of $1.98.

Get the Latest News and Ratings for CRBU and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Caribou Biosciences and its competitors.

CRBU Analyst Ratings Over Time

Type	Current Forecast 10/1/23 to 9/30/24	1 Month Ago 9/1/23 to 8/31/24	3 Months Ago 7/3/23 to 7/2/24	1 Year Ago 10/1/22 to 10/1/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.25	$15.00	$15.25	$25.33
Forecasted Upside	468.18% Upside	594.44% Upside	853.13% Upside	429.99% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Trump’s weapon lurks in abandoned America (Ad)

Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…

Go here now to watch my new documentary

CRBU Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRBU Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Caribou Biosciences Stock vs. The Competition

Type	Caribou Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	468.18% Upside	818.78% Upside	6.17% Upside
News Sentiment Rating	Positive News See Recent CRBU News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/3/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00	+334.78%
8/7/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$14.00 ➝ $14.00	+610.66%
6/3/2024	Evercore ISI 2 of 5 stars	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline	$13.00 ➝ $3.00	+4.17%
5/16/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00	+426.31%
11/8/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
9/5/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$37.00 ➝ $30.00	+410.20%
3/17/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$27.00 ➝ $25.00	+404.03%
3/10/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$36.00 ➝ $32.00	+480.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:28 AM ET.

CRBU Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Caribou Biosciences is $11.25, with a high forecast of $19.00 and a low forecast of $3.00.
: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Caribou Biosciences in the last year. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRBU shares.
: According to analysts, Caribou Biosciences's stock has a predicted upside of 468.18% based on their 12-month stock forecasts.
: Caribou Biosciences has been rated by research analysts at HC Wainwright, and Royal Bank of Canada in the past 90 days.
: Analysts like Caribou Biosciences less than other "medical" companies. The consensus rating score for Caribou Biosciences is 2.75 while the average consensus rating score for "medical" companies is 2.78. Learn more on how CRBU compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Wall St. Icon: Looming Financial Tsunami will Wipe Out the 1% (Ad)

Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American economy like a tsunami. It doesn't matter if you're blue collar, white collar, working, or retired. He says, "I am literally afraid for my family's future. I'm taking drastic steps to prepare for what I know will inevitably happen next."

Click here to see his new prediction

This page (NASDAQ:CRBU) was last updated on 9/30/2024 by MarketBeat.com Staff

From Our Partners